Search
for

    Learn

    5 / 7 results

      learn Exosomes

      Microscopic delivery system that sends growth-promoting signals to hair follicles

      learn Osteopontin

      signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

      learn Alfatradiol

      a synthetic estrogen used topically as an anti-androgen

      learn GHK-Cu

      a copper peptide showing promise in both regrowth and reversing gray hair

      learn Follistatin

      glycoprotein that inhibits TGF-β and promotes hair growth by antagonizing activin

    Research

    5 / 1000+ results

    Community Join

    5 / 214 results

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  135 upvotes 1 year ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community Tazarotene shows strong standalone hair regrowth potential, not just a Minoxidil enhancer. Backed by VEGF, HF regeneration, and angiogenesis pathways. Here’s why.

      in Research/Science  132 upvotes 2 weeks ago
      Tazarotene shows potential as a standalone treatment for hair regrowth by stimulating new hair follicle formation and promoting angiogenesis, similar to microneedling effects. It can be used topically without minoxidil, but users should start with a low concentration to avoid irritation.

      community Pyrilutamide ,the molecule’s true nature

      in Research  302 upvotes 11 months ago
      Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 11 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.